ENA RESPIRATORY
Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines. Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterial dissemination to the lungs.
ENA RESPIRATORY
Industry:
Biotechnology Health Diagnostics Medical
Founded:
2014-01-01
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.enarespiratory.com
Total Employee:
11+
Status:
Active
Total Funding:
50 M AUD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Digital Ocean
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Board_member
Board_member
2021-06-01
Current Employees Featured
Christophe Demaison Co-founder and CEO & Director @ Ena Respiratory
Co-founder and CEO & Director
Founder
Investors List
Brandon Capital Partners
Brandon Capital Partners investment in Venture Round - Ena Respiratory
Uniseed Ventures
Uniseed Ventures investment in Venture Round - Ena Respiratory
Minderoo Foundation
Minderoo Foundation investment in Venture Round - Ena Respiratory
Stoic VC
Stoic VC investment in Venture Round - Ena Respiratory
Ruth Tal-Singer
Ruth Tal-Singer investment in Venture Round - Ena Respiratory
CSL
CSL investment in Series A - Ena Respiratory
AustralianSuper
AustralianSuper investment in Series A - Ena Respiratory
MRCF Biomedical Translation Fund
MRCF Biomedical Translation Fund investment in Series A - Ena Respiratory
Stoic VC
Stoic VC investment in Series A - Ena Respiratory
Uniseed Ventures
Uniseed Ventures investment in Series A - Ena Respiratory
Official Site Inspections
http://www.enarespiratory.com Semrush global rank: 5.92 M Semrush visits lastest month: 1.39 K
- Host name: 104.21.48.189
- IP address: 104.21.48.189
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ena Respiratory"
About – ENA Respiratory
ENA Respiratory is a clinical-stage pharmaceutical company. We are tackling the resulting serious complications (sequelae) of respiratory viral infections through the development of host …See details»
Leadership – ENA Respiratory
Grant Mclachlan, PhD Director, CMC Program Management. Grant joined ENA Respiratory in 2020, overseeing the company’s CMC activities. He brings over 25 years of experience in drug …See details»
ENA Respiratory Announces Peer-Reviewed Publication of First …
3 days ago The company’s lead product, INNA-051, is a potent agonist of toll-like receptor 2/6 (TLR2/6) which plays a key role in recognising pathogens and triggering the innate immune …See details»
Ena Respiratory Company Profile: Overview and Full News Analysis
Enarespiratory.com. Overview: Ena Respiratory. Ena Respiratory, a clinical-stage pharmaceutical company based in Victoria, Australia, is focused on developing innate immune modulators in …See details»
Ena Respiratory Company Profile 2024: Valuation, …
Ena Respiratory General Information Description. Developer of immunomodulators designed to prevent respiratory viral infections. The company's products allow for topical delivery to the airways in order to target …See details»
ENA RESPIRATORY PTY LTD - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for ENA RESPIRATORY PTY LTD of Melbourne, VICTORIA. Get the latest business insights from Dun …See details»
ENA Respiratory - LinkedIn
ENA Respiratory is a clinical-stage pharmaceutical company developing INNA-051, an intranasal innate immune modulator for the prevention of complications resulting from respiratory viral ...See details»
ENA Respiratory and the COPD Foundation Partner to Develop …
Feb 23, 2022 For more information, please visit https://enarespiratory.com About The COPD Foundation and COPD360Net The COPD Foundation is a not-for-profit organization …See details»
Exploristics signs collaboration agreement with ENA …
Sep 18, 2023 BELFAST, United Kingdom — Exploristics is pleased to announce today a collaboration with ENA Respiratory using Exploristics’ innovative study simulation software platform KerusCloud to establish a more efficient data …See details»
Recommended Stories
3 days ago When compared to placebo, prophylactic administration of INNA-051 was associated with significantly increased expression of multiple host defense genes and shorter duration of …See details»
ENA Respiratory Begins Phase I Study of COVID-19 Preventative …
Amid a new outbreak of COVID-19 in the Sydney area, the organization is actively recruiting people interested in participating in the study. Earlier research conducted by Public Health …See details»
ENA Respiratory Announces Peer-Reviewed Publication of
3 days ago ENA Respiratory Announces Peer-Reviewed Publication of First Time in Humans and Influenza Virus Challenge Studies with the Intranasal Innate Immunomodulator INNA-051See details»
Publications – ENA Respiratory
Oct 22, 2024 The COPD Foundation’s COPD360Net Initiative Approach to Patient-Centric Drug Development: A Case Study in Using Patient Surveys to Inform New Treatments for Viral …See details»
Ena Respiratory | Insights
Mar 9, 2022 Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Ena Respiratory Pty Ltd Asset Profile | Preqin
Www.enarespiratory.com Verticals Manufacturing Company Stage Series A Total Amount Raised Subscriber access only Time to go Pro Get Preqin Pro for unrestricted access to 600,000+ …See details»
Board – ENA Respiratory
Liza Yeo Non-Executive Director. Liza is an Investment Manager at Uniseed. She has spent 20 years of her career in Roche and a number of Global Contract Research Organisations (CROs).See details»
ENA Respiratory Announces Peer-Reviewed Publication ... - The …
3 days ago About ENA Respiratory . ENA Respiratory is a clinical-stage pharmaceutical company tackling serious respiratory viral infections through the development of host defence …See details»
Ena Respiratory - Company Profile - Tracxn
Oct 15, 2024 Ena Respiratory ranks 32nd among 95 active competitors. 31 of its competitors are funded while 19 have exited. Overall, Ena Respiratory and its competitors have raised over …See details»
News – ENA Respiratory
ENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral 5 September 2024. New US $3.13 million DOD contract extension to …See details»